EDUARDO LUIS ANGUITA MANDLY-rekin lankidetzan egindako argitalpenak (9)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

    Science translational medicine, Vol. 16, Núm. 734, pp. eadg7962

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

    Scientific Reports, Vol. 11, Núm. 1

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

2018

  1. A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia

    Oncotarget, Vol. 9, Núm. 40, pp. 26019-26031

  2. Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology

    British Journal of Haematology

2017

  1. PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

    PLoS ONE, Vol. 12, Núm. 7